| RPP # (Release Date) | Requirement Topic | Description | Requiring Office | Submission Due Date |
|---|---|---|---|---|
| RPP 25-11-Smart Ab (9/10/2025) | Antibody (Ab) Advanced Manufacturing Capability Improvement: Smart Technologies | Monoclonal Antibodies (mAbs) played a central role in the US response to the outbreaks of important human pathogens such as anthrax, Ebola, RSV and SARS CoV-2. Advancing beyond the demonstrated manufacturing performance of mAbs for a rapid response, BARDA is seeking to improve (enhance) the speed and efficiency of antibody production. This effort is directed at developing and implementing FDA Advanced Manufacturing (Appendix 1, Reference #1) goals within the antibody manufacturing environment. Innovations of most interest are those that rapidly scale manufacturing capabilities (scalability), create a distributed network of manufacturing sites (portability), improve cost-efficiency of manufacturing processes, and create new tools that can address drug shortages in support of the emergency preparedness and response mission of the Biomedical Advanced Research and Development Authority (BARDA). | BARDA | 10/01/2025 |
| Type | Release Date | Requirement Topic | Closed Date |
|---|---|---|---|
| Market Research | 08/06/2025 | Market Research Survey: Personal Protective Equipment Manufacturing | 08/26/2025 |
| Market Research | 03/26/2025 | Market Research survey for Adherent Cell Culture Manufacturing | 04/09/2025 |
| Market Research | 11/07/2024 | Market Research Survey for Pichia Expression System Capabilities | 11/21/2024 |
| Request for Information | 03/20/2024 | Request for Information regarding Manufacturing Optimization for Filovirus Human Monoclonal Antibodies | 04/20/2024 |
| RPP-24-05-N95 | 08/02/2025 | Sustainment of N95 Respirator Manufacturing Capacity | 08/22/2024 |
| RPP-24-07-mAbs | 06/24/2024 | Manufacturing Optimization for Filovirus Monoclonal Antibodies | 08/05/2024 |
| RPP-24-06-Pipette | 06/27/2024 | Industrial Base Expansion of injection molded pipette tips and centrifuge tubes for use in the vaccine manufacturing and pandemic response supply chain | 07/25/2024 |
| RPP-24-03-Sterilization | 03/01/2024 | Sterilization Capacity for Vaccines and Therapeutics | 03/28/2024 |
| RPP-24-02-KSM-API | 02/21/2024 | Production of Drug Substances and Drug Products at Commercial Scale | 03/20/2024 |
| RPP-24-01-SmallMol | 01/11/2024 | Production of Biologically Derived Small Molecule Regulatory Starting Materials and/or Active Pharmaceutical Ingredients at Commercial Scale | 02/01/2024 |
